Loading...
•
Jun 30, 2025
Aytu BioScience Q4 2025 Earnings Report
Aytu BioPharma reported a higher Q4 net loss as it ramped up preparations for the commercial launch of EXXUA.
Key Takeaways
Aytu BioPharma's Q4 showed stable revenue and flat adjusted EBITDA, but the quarter ended with a larger net loss driven by impairment charges and derivative warrant liabilities linked to the upcoming EXXUA launch.
Revenue by Segment
Forward Guidance
Aytu expects the commercial launch of EXXUA in Q4 calendar 2025 to drive future growth and position the company strongly in the CNS therapeutic area.
Positive Outlook
- EXXUA commercial launch on track for Q4 calendar 2025
- Expansion into the $22B U.S. MDD market
- CNS-focused salesforce and infrastructure in place
- Pediatric Portfolio showed strong revenue growth
- 9th consecutive quarter of positive adjusted EBITDA
Challenges Ahead
- Significant net loss driven by impairment and warrant liabilities
- Decline in ADHD Portfolio revenue
- Gross margin decreased from 76% to 68%
- Impact of EXXUA prep on operating costs
- Restructuring and site closure expenses affected profitability
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...